Cargando…

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells

BACKGROUND: This study investigates the docetaxel-resistant mechanism and explores the effect of tea polyphenols (TP) on autophagy and its related mechanism in human castration-resistant prostate cancer (CRPC) cell lines PC3 and DU145. METHODS: Immunofluorescence assay and annexin V-FITC/PI double s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Quan, He, Wei-Yang, Zeng, Yi-Zhou, Hossain, Arman, Gou, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2018
Materias:	Urology - Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878207/ https://www.ncbi.nlm.nih.gov/pubmed/29460131 http://dx.doi.org/10.1007/s11255-018-1801-5

Ejemplares similares

An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
por: Carles, Joan, et al.
Publicado: (2018)

Diethylstilbestrol in the Treatment of Castration-resistant Prostate Cancer: A Lower-middle-income Country Experience
por: Ali, Azfar, et al.
Publicado: (2019)

Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials
por: Tarrar, Talha Azam, et al.
Publicado: (2022)

Unusual presentation of castrate-resistant prostate cancer with urethral and inguinal nodal metastasis
por: Jindal, Tarun, et al.
Publicado: (2021)

Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial
por: Miyake, Hideaki, et al.
Publicado: (2023)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol
por: Kvorning Ternov, Klara, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy
por: Zeng, Jin, et al.
Publicado: (2018)

Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation
por: Graff, Julie N, et al.
Publicado: (2015)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
por: Lin, Jian-Zhong, et al.
Publicado: (2017)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

Cleistanthins A and B Ameliorate Testosterone-Induced Benign Prostatic Hyperplasia in Castrated Rats by Regulating Apoptosis and Cell Differentiation
por: S C, Santosh Kumar, et al.
Publicado: (2022)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
por: Tanaudommongkon, Irin, et al.
Publicado: (2020)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
por: He, Yundong, et al.
Publicado: (2016)

Overcoming docetaxel resistance in prostate cancer: a perspective review
por: Hwang, Clara
Publicado: (2012)

AB122. MicroRNA-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence
por: Xu, Chuanliang, et al.
Publicado: (2014)

SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway
por: Du, Zhongbo, et al.
Publicado: (2022)

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
por: Huang, Yujie, et al.
Publicado: (2022)

Hypoxia‐inducible factor 1A inhibition overcomes castration resistance of prostate tumors
por: Terzic, Julie, et al.
Publicado: (2023)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
por: Li, Senmao, et al.
Publicado: (2021)

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model
por: Nguyen, H G, et al.
Publicado: (2014)

Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
por: Qiu, Xiaofu, et al.
Publicado: (2019)

KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy
por: Jia, Jing, et al.
Publicado: (2019)

Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/β-Catenin Signaling by XAV939
por: Pudova, Elena, et al.
Publicado: (2022)

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
por: Ryan, Charles J., et al.
Publicado: (2021)

JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
por: Cai, Xiang, et al.
Publicado: (2023)

Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells
por: Cánovas, Verónica, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fgpliqo65b3k296cfsk7cleqhb